Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) has signed an exclusive licence agreement with UWA, granting worldwide rights to a rapidly growing portfolio of selective serotonin-releasing agents. (See Appendix for Key Commercial Terms). These novel compounds, realised through a UWA–Emyria research partnership launched in 2021,2 include potential next-generation treatments…
Locksley Resources Limited (ASX:LKY) (“Locksley” or “the Company”) is pleased to announce high-grade antimony grades up to 46% Sb…
The World Gold Council (WGC) has released its latest Gold Demand Trends report, saying that total demand for the…
Cardiex Limited (ASX:CDX) (the “Company”) is pleased to report its activities during the September quarter 2024. Highlights: Manufacturing of…
Those interested in the lithium sector and investing in lithium stocks are often curious about which countries produce the…
Bitcoin, the most well-known cryptocurrency, paved the way for the cryptocurrency asset class. Now the cryptocurrency of choice, its…
The exorbitant cost of pharmaceutical drugs in the US has been a contentious issue for years, with the Republican…
In her view, it’s only a matter of time before both precious metals are squeezed higher. ‘We’ll see, but…
Platinum-group metals (PGMs) include platinum, palladium, rhodium and other metals, all of which are prized for their durability, resistance…